Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 508 participants.

Also called NCT01788358

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 508 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01788358
  • EudraCT 2012-004515-32
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Germany, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01788358. Allocation not applicable; no masking; primary purpose treatment. Start 2013-02-14 (actual); primary completion 2014-05-01 (actual). Results posted on 2015-08-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
Condition
Hypertension
Intervention (Drug)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Intervention (Drug)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Intervention (Drug)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Intervention (Drug)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01788358
Content hash
c74a615e4a99203a520eb7161962e431b363fe4be907b429fbdedb328871e829